Green Cross Medical Science Corporation (142280) - Net Assets
Based on the latest financial reports, Green Cross Medical Science Corporation (142280) has net assets worth ₩56.08 Billion KRW (≈ $38.00 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩96.94 Billion ≈ $65.70 Million USD) and total liabilities (₩40.86 Billion ≈ $27.69 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 142280 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩56.08 Billion |
| % of Total Assets | 57.85% |
| Annual Growth Rate | 3.58% |
| 5-Year Change | 28.38% |
| 10-Year Change | 72.69% |
| Growth Volatility | 67.92 |
Green Cross Medical Science Corporation - Net Assets Trend (2014–2025)
This chart illustrates how Green Cross Medical Science Corporation's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 142280 market cap.
Annual Net Assets for Green Cross Medical Science Corporation (2014–2025)
The table below shows the annual net assets of Green Cross Medical Science Corporation from 2014 to 2025. Also explore Green Cross Medical Science Corporation (142280) equity growth momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩46.37 Billion ≈ $31.42 Million |
+12.50% |
| 2024-12-31 | ₩41.21 Billion ≈ $27.93 Million |
+11.62% |
| 2023-12-31 | ₩36.92 Billion ≈ $25.02 Million |
+11.03% |
| 2022-12-31 | ₩33.25 Billion ≈ $22.54 Million |
-7.92% |
| 2021-12-31 | ₩36.11 Billion ≈ $24.47 Million |
-36.04% |
| 2020-12-31 | ₩56.47 Billion ≈ $38.27 Million |
+13.90% |
| 2019-12-31 | ₩49.58 Billion ≈ $33.60 Million |
+223.18% |
| 2018-12-31 | ₩15.34 Billion ≈ $10.40 Million |
-33.97% |
| 2017-12-31 | ₩23.23 Billion ≈ $15.75 Million |
-13.46% |
| 2016-12-31 | ₩26.85 Billion ≈ $18.20 Million |
-6.99% |
| 2015-12-31 | ₩28.87 Billion ≈ $19.56 Million |
-8.37% |
| 2014-12-31 | ₩31.50 Billion ≈ $21.35 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Green Cross Medical Science Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 26.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩18.85 Billion | 42.49% |
| Other Components | ₩25.51 Billion | 57.51% |
| Total Equity | ₩44.36 Billion | 100.00% |
Green Cross Medical Science Corporation Competitors by Market Cap
The table below lists competitors of Green Cross Medical Science Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Golden Energy Offshore Services AS
OL:GEOS
|
$48.65 Million |
|
Bluebird bio Inc
NASDAQ:BLUE
|
$48.67 Million |
|
Quartiers Properties AB
ST:QUART
|
$48.68 Million |
|
Feytech Holdings Berhad
KLSE:5322
|
$48.69 Million |
|
Cherrybro co.Ltd
KQ:066360
|
$48.61 Million |
|
Hyundai Industrial Co. Ltd
KQ:170030
|
$48.61 Million |
|
Indonesia Energy
NYSE MKT:INDO
|
$48.56 Million |
|
Digihost Technology Inc
V:DGHI
|
$48.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Green Cross Medical Science Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 41,214,438,830 to 44,358,636,420, a change of 3,144,197,590 (7.6%).
- Net income of 3,666,195,480 contributed positively to equity growth.
- Other factors decreased equity by 521,997,890.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩3.67 Billion | +8.26% |
| Other Changes | ₩-522.00 Million | -1.18% |
| Total Change | ₩- | 7.63% |
Book Value vs Market Value Analysis
This analysis compares Green Cross Medical Science Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.62x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.33x to 1.62x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩2482.17 | ₩3300.00 | x |
| 2017-12-31 | ₩2086.07 | ₩3300.00 | x |
| 2018-12-31 | ₩1377.33 | ₩3300.00 | x |
| 2019-12-31 | ₩2353.26 | ₩3300.00 | x |
| 2020-12-31 | ₩2680.28 | ₩3300.00 | x |
| 2021-12-31 | ₩1714.26 | ₩3300.00 | x |
| 2022-12-31 | ₩1577.38 | ₩3300.00 | x |
| 2023-12-31 | ₩1636.40 | ₩3300.00 | x |
| 2024-12-31 | ₩1898.68 | ₩3300.00 | x |
| 2025-12-31 | ₩2040.23 | ₩3300.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Green Cross Medical Science Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.26%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.38%
- • Asset Turnover: 1.20x
- • Equity Multiplier: 2.04x
- Recent ROE (8.26%) is above the historical average (-11.37%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 11.80% | 4.57% | 1.56x | 1.65x | ₩566.58 Million |
| 2015 | 2.53% | 0.82% | 1.23x | 2.52x | ₩-2.16 Billion |
| 2016 | -7.04% | -2.19% | 1.35x | 2.37x | ₩-4.58 Billion |
| 2017 | -5.80% | -1.37% | 1.63x | 2.61x | ₩-3.67 Billion |
| 2018 | -69.82% | -12.41% | 1.35x | 4.17x | ₩-12.24 Billion |
| 2019 | -32.69% | -17.22% | 1.06x | 1.79x | ₩-21.16 Billion |
| 2020 | 11.90% | 5.92% | 1.07x | 1.87x | ₩1.07 Billion |
| 2021 | -58.71% | -20.85% | 1.06x | 2.65x | ₩-24.81 Billion |
| 2022 | -10.77% | -3.17% | 1.17x | 2.90x | ₩-6.91 Billion |
| 2023 | 5.21% | 1.91% | 1.04x | 2.62x | ₩-1.65 Billion |
| 2024 | 8.69% | 3.45% | 1.18x | 2.13x | ₩-540.37 Million |
| 2025 | 8.26% | 3.38% | 1.20x | 2.04x | ₩-769.67 Million |
Industry Comparison
This section compares Green Cross Medical Science Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $443,145,540,997
- Average return on equity (ROE) among peers: 4.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Green Cross Medical Science Corporation (142280) | ₩56.08 Billion | 11.80% | 0.73x | $48.62 Million |
| Dongwha Pharm.Co.Ltd (000020) | $297.40 Billion | 3.39% | 0.25x | $94.67 Million |
| Yuhan Corp. (000100) | $862.60 Billion | 14.22% | 0.20x | $3.79 Billion |
| Yuhan Corp Preferred (000105) | $2.36 Trillion | 8.22% | 0.36x | $45.29 Million |
| Yuyu Pharma (000220) | $117.04 Billion | 1.10% | 0.32x | $42.11 Million |
| Yuyu Pharma Inc (000225) | $128.69 Billion | -1.72% | 0.50x | $14.65 Million |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $31.49 Million |
| Ildong Holdings Co Ltd (000230) | $174.64 Billion | 0.37% | 0.57x | $47.08 Million |
| Samil Pharm (000520) | $66.60 Billion | 0.00% | 0.82x | $111.64 Million |
| Donga Socio Holdings (000640) | $208.05 Billion | 10.39% | 1.63x | $408.39 Million |
| Jw Pharmac (001060) | $85.47 Billion | 8.63% | 3.65x | $424.83 Million |
About Green Cross Medical Science Corporation
GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company's products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases. It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CER… Read more